OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis

[en] The objective of this work was to describe requirements for inclusion of soluble biomarkers in osteoarthritis (OA) clinical trials and progress toward OA-related biomarker qualification. The Guidelines for Biomarkers Working Group, representing experts in the field of OA biomarker research from both academia and industry, convened to discuss issues related to soluble biomarkers and to make recommendations for their use in OA clinical trials based on current knowledge and anticipated benefits. This document summarizes current guidance on use of biomarkers in OA clinical trials and their utility at five stages, including preclinical development and phase I to phase IV trials. As demonstrated by this summary, biomarkers can provide value at all stages of therapeutics development. When resources permit, we recommend collection of biospecimens in all OA clinical trials for a wide variety of reasons but in particular, to determine whether biomarkers are useful in identifying those individuals most likely to receive clinically important benefits from an intervention; and to determine whether biomarkers are useful for identifying individuals at earlier stages of OA in order to institute treatment at a time more amenable to disease modification.

Disciplines :

Rheumatology

Author, co-author :

Kraus, V. B.

Blanco, F. J.

Englund, M.

Henrotin, Yves ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)

Lohmander, L. S.

Losina, E.

Onnerfjord, P.

Persiani, S.

Language :

English

Title :

OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis

Publication date :

2015

Journal title :

Osteoarthritis and Cartilage

ISSN :

1063-4584

eISSN :

1522-9653

Publisher :

Elsevier, United Kingdom

Volume :

Issue :

Pages :

686-97

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.ncbi.nlm.nih.gov/pubmed/25952342

Available on ORBi :

since 20 January 2016

Statistics

Number of views

29 (1 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Altman R., Brandt K., Hochberg M., Moskowitz R., Bellamy N., Bloch D.A., et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage 1996, 4:217-243.
Hunter D.J., Losina E., Guermazi A., Burstein D., Lassere M.N., Kraus V. Apathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets 2010, 11:536-545.
Hunter D.J., Nevitt M., Losina E., Kraus V. Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res Clin Rheumatol 2014, 28:61-71.
Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002, 18:41-46.
Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007, 81:104-107.
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working G.
FDA Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools January, 2014, Silver Spring, MD.
Saxne T., Heinegard D., Wollheim F.A. Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. Ann Rheum Dis 1986, 45:491-497.
Lotz M., Martel-Pelletier J., Christiansen C., Brandi M.L., Bruyere O., Chapurlat R., et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 2013, 72:1756-1763.
Homandberg G.A., Hui F., Wen C., Purple C., Bewsey K., Koepp H., et al. Fibronectin-fragment-induced cartilage chondrolysis is associated with release of catabolic cytokines. Biochem J 1997, 321(Pt 3):751-757.
Pulai J.I., Chen H., Im H.J., Kumar S., Hanning C., Hegde P.S., et al. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. JImmunol 2005, 174:5781-5788.
Knudson W., Casey B., Nishida Y., Eger W., Kuettner K.E., Knudson C.B. Hyaluronan oligosaccharides perturb cartilage matrix homeostasis and induce chondrocytic chondrolysis. Arthritis Rheum 2000, 43:1165-1174.
Campo G.M., Avenoso A., D'Ascola A., Prestipino V., Scuruchi M., Nastasi G., et al. Hyaluronan differently modulates TLR-4 and the inflammatory response in mouse chondrocytes. Biofactors 2012, 38:69-76.
Homandberg G.A., Wen C., Hui F. Cartilage damaging activities of fibronectin fragments derived from cartilage and synovial fluid. Osteoarthritis Cartilage 1998, 6:231-244.
Band P.A., Heeter J., Wisniewski H.G., Liublinska V., Pattanayak C.W., Karia R.J., et al. Hyaluronan molecular weight distribution is associated with the risk of knee osteoarthritis progression. Osteoarthritis Cartilage 2015, 23:70-76.
Institute of Medicine Evaluation of biomarkers and surrogate endpoints in chronic disease. Brief Report 2010, 336. National Academies Press, Washington, DC, Institute of Medicine. C. Micheel, J. Ball (Eds.).
Committee on the Review of Omics-based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy. Evolution of Translational Omics: Lessons Learned and the Path Forward 2012, 300. Institute of Medicine. C. Micheel, S. Nass, G. Omenn (Eds.).
Ball J., Albert M., Apple F., Califf R., De Gruttola V., DeMets D., et al. Evaluation of biomarkers and surrogate endpoints in chronic disease. Brief Report 2010, 4. Institute of Medicine, Washington, DC.
Kraus V.B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011, 19:515-542.
FDA New drug, antibiotic, and biological drug product regulations: accelerated approval. Final rule. Fed Regist 1992, 57:58942. Friday, December 11. Washington, DC.
FDA, CDER and CBER Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics May 2014.
Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
Driscoll T., Jacklyn G., Orchard J., Passmore E., Vos T., Freedman G., et al. The global burden of occupationally related low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014, 73:975-981.
Smith E., Hoy D.G., Cross M., Vos T., Naghavi M., Buchbinder R., et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014, 73:1462-1469.
Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006, 14:723-727.
Onnerfjord P., Khabut A., Reinholt F.P., Svensson O., Heinegard D. Quantitative proteomic analysis of eight cartilaginous tissues reveals characteristic differences as well as similarities between subgroups. JBiol Chem 2012, 287:18913-18924.
Catterall J.B., Hsueh M.F., Stabler T.V., McCudden C.R., Bolognesi M., Zura R., et al. Protein modification by deamidation indicates variations in joint extracellular matrix turnover. JBiol Chem 2012, 287:4640-4651.
Schalken J.A. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 2010, 58:19-20.
Keen H.I., Mease P.J., Bingham C.O., Giles J.T., Kaeley G., Conaghan P.G. Systematic review of MRI, ultrasound, and scintigraphy as outcome measures for structural pathology in interventional therapeutic studies of knee arthritis: focus on responsiveness. JRheumatol 2011, 38:142-154.
Fleming T.R., Powers J.H. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012, 31:2973-2984.
European Commission HRD Stratification biomarkers in personalised medicine. Biomarkers for Patient Stratification 2010, European Commission, DG Research, Brussels.
Simoncell T., Barclay L., Bouri K., Burns K., Cook K., Filice R., et al. Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development October, 2013, 1-61. FDA, Silver Spring, MD.
Tucker M. FDA report Outlines approach to personalized medicine. Medscape 2013.
FDA and CDER Guidance for Industry: Qualification Process for Drug Development Tools October, 2010, Silver Spring, MD.
Kumar C., van Gool A. Biomarkers in translational and personalized medicine. Comprehensive Biomarker Discovery and Validation for Clinical Application 2013, 3-39. R. Horvatovich, R. Rainer Bischoff (Eds.).
Amur S., Frueh F.W., Lesko L.J., Huang S.M. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med 2008, 2:305-311.
Floyd E., McShane T.M. Development and use of biomarkers in oncology drug development. Toxicol Pathol 2004, 32(Suppl 1):106-115.
ABPI Guidelines for Phase 1 Clinical Trials 2012, Association of the British Pharmaceutical Industry, London. O. Schmidt, M. Boyce (Eds.).
Danhof M., de Jongh J., De Lange E.C., Della Pasqua O., Ploeger B.A., Voskuyl R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007, 47:357-400.
Ploeger B.A., van der Graaf P.H., Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet 2009, 24:3-15.
Zhang L., Sinha V., Forgue S.T., Callies S., Ni L., Peck R., et al. Model-based drug development: the road to quantitative pharmacology. JPharmacokinet Pharmacodyn 2006, 33:369-393.
Dodds M.G., Salinger D.H., Mandema J., Gibbs J.P., Gibbs M.A. Clinical trial simulation to inform phase 2: comparison of concentrated vs. distributed first-in-patient study designs inpsoriasis. CPT Pharmacometrics Syst Pharmacol 2013, 2:e58.
Bornkamp B., Pinheiro J., Bretz F. MCP-Mod - an R package for the design and analysis of dose finding studies. JStat Softw 2008, 29:1-23.
European Medicines Agency Draft Qualification Opinion of MCP-Mod as an efficient 5 statistical methodology for model-based design and 6 analysis of Phase II dose finding studies under model 7 uncertainty. Department PDSS 2013, European Medicines Agency, London.
Friberg L.E. Tutorials on the foundations of pharmacometrics and systems pharmacology. CPT Pharmacometrics Syst Pharmacol 2013, 2:e53.
Freidlin B., Korn E.L. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014, 11:81-90.
FDA, CDER, CBER and CDRH Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products December, 2012, Silver Spring, MD.
FDA, CDER and CVM Guidance for Industry: Bioanalytical Method Validation. ed. Revision 1 September, 2013, Silver Spring, MD.
Rai A.J., Gelfand C.A., Haywood B.C., Warunek D.J., Yi J., Schuchard M.D., et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5:3262-3277.
Whiteaker J.R., Zhao L., Anderson L., Paulovich A.G. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010, 9:184-196.
Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011, 8:61-79.
Marquette C.A., Corgier B.P., Blum L.J. Recent advances in multiplex immunoassays. Bioanalysis 2012, 4:927-936.
Mischak H., Allmaier G., Apweiler R., Attwood T., Baumann M., Benigni A., et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010, 2:46ps42.
Carr S.A., Abbatiello S.E., Ackermann B.L., Borchers C., Domon B., Deutsch E.W., et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014, 13:907-917.
Chambers A.G., Percy A.J., Simon R., Borchers C.H. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics 2014, 11:137-148.
Dufield D.R., Nemirovskiy O.V., Jennings M.G., Tortorella M.D., Malfait A.M., Mathews W.R. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem 2010, 406:113-123.
Skates S.J., Gillette M.A., LaBaer J., Carr S.A., Anderson L., Liebler D.C., et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. JProteome Res 2013, 12:5383-5394.
Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
Brenner D.E., Normolle D.P. Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev 2007, 16:1918-1920.
Pham T., van der Heijde D., Altman R.D., Anderson J.J., Bellamy N., Hochberg M., et al. OMERACT-OARSI initiative: osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004, 12:389-399.
Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Ann Intern Med 2003, 138:40-44.